Topical therapies are used by most psoriasis patients either alone or in combination with systemic therapies and phototherapy. The objective of this paper is to review the different topical therapies to treat mild to moderate psoriasis, including corticosteroids, vitamin D analogs, tazarotene, topical calcineurin inhibitors, anthralin, salicylic acid, and coal tar and assess their effectiveness and tolerability. Topical therapies are important for treating psoriasis and will continue to play a major role even as new systemic therapies emerge.
KooJ.Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin.1996; 14(3): 485–96.
2.
PearceD.J., SpencerL., HuJ., BalkrishnanR., FleischerA.B.Jr., FeldmanS.R.Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatol Treat.2004; 15(4): 235–8.
3.
StrowdL.C., YentzerB.A., FleischerA.B.Jr., FeldmanS.R.Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol.2009; 60(3): 478–81.
MckenzieA.W., StoughtonR.B.Method for comparing percutaneous absorption of steroids. Arch Dermatol.1962; 86: 608–10.
10.
GoldbergB., HartdegenR., PresburyD., SmithE.H., YawalkarS.A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol.1991; 25(6 part 2): 1145–8.
11.
BlumG., YawalkarS.A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol.1991; 25(6 Part 2) 1153–6.
12.
JarrattM.T., ClarkS.D., DavinR.C., SwinyerL.J., SafleyC.F., BrodellR.T., YuK.Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis.2006; 78: 348–54.
13.
LebwohlM., ShererD., WashenikK., KruegerG.G., MenterA., KooJ.A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol.2002; 41: 269–74.
14.
DecroixJ., PresH., TsankovN., PoncetM., ArsonnaudS.Clobetasol propionate lotion in the treatment of moderate to severe plaque-type paoriasis. Cutis.2004; 74: 201–206.
15.
GoaK.L.Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids: a review. Drugs.1988; 36(suppl 5): 51–61.
KuboT., KojimaA., YamazoeS., UeshimaK., YamamotoT., HirasawaY.Osteonecrosis of the femoral head that developed after long-term topical steroid application. J Orthop Sci.2001; 6(1): 92–4.
20.
KatzH.I., HienN.T., PrawerS.E., MastbaumL.I., MooneyJ.J., SamsonC.R.Superpotent topical steroid treatment of psoriasis vulgaris: clinical efficacy and adrenal function. J Am Acad Dermatol.1987; 16: 804–11.
21.
MunroD.D.The effect of percutaneously absorbed steroids on hypothalamic-pituitary-adrenal function after intensive use in in-patients. Br J Dermatol.1976; 94(suppl 12): 67–76.
du VivierA., StoughtonR.B.Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol.1975; 111: 581–3.
24.
du VivierA.Tachyphylaxis to topically applied steroids. Arch Dermatol.1976; 112: 1245–8.
25.
MillerJ.J., RolingD., MargolisD., GuzzoC.Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol.1999; 41(4): 546–9.
26.
RichardsH.L., FortuneD.G., O'SullivanT.M., MainC.J., GriffithsC.E.Patients with psoriasis and their compliance with medicinesJ Am Acad Dermatol.1999; 41: 581–3.
27.
StormA., BenfeldtE., Ejdrup, AndersonS., SerupJ.A prospective study of patient adherence to topical treatments: 95% of patients underdose. J Am Acad Dermatol.2009; 59: 975–98.
28.
HansenC.M., MathiasenI.S., BinderupL.The anti-proliferative and differentiation-induced effects of vitamin D analogs are not determined by the binding affinity for the vitamin D receptor alone. J Invest Dermatol Symp Proc.1996; 1: 44–8.
29.
LeaA.P., GoaK.L.Calcipotriol: a review of its pharmacological properties and therapeutic efficacy in the management of psoriasis. Clin Immunother.1996; 5: 230–48.
30.
ScottL.J., DunnC.J., GoaK.L.Calcipotriol ointment: a review of its use in the management of psoriasis. Am J Clin Dermatol.2001; 2(2): 95–120.
31.
HightonA., QuellJ.Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol.1995; 32: 67–72.
32.
CunliffeW.J., Berth-JonesJ., ClaudyA., FairissG., GoldinD., GrattonD.Comparative study of calcipotriol (MC 903) ointment and betamethasone 17–valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol.1992; 26(5, part 1): 736–43.
33.
BruceS., EpinetteW.W., FunicellaT., IsonA., JonesE.L., LossR.Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol.1994; 31(5, part 1): 755–9.
34.
GreenC., GanpuleM., HarrisD., KavanaghG., KennedyC., MallettR.Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol.1994; 130: 483–7.
35.
CullenS.I., and Calcipotriene Study Group. Long-term effectiveness and safety of topical calcipotriene for psoriasis. South Med J.1996; 89: 1053–6.
36.
PoynerT., HughesI.W., DassB.K., AdnittP.Long-term treatment of chronic plaque psoriasis with calcipotriol. J Dermatol Treat.1993; 4: 173–7.
37.
OranjeA.P., MarcouxD., SvenssonA., PrendivilleJ., KrafchikB., TooleJ.Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol.1997; 36: 203–8.
38.
DarleyC.R., CunliffeW.J., GreenC.M., HutchinsonP.E., KlaberM.R., DownesN.Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol.1996; 135: 390–3.
39.
ZhuX., WangB., ZhaoG., GuJ., ChenZ., BriantaisP.An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3mg/g ointment vs. calcipotriol 50 mg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol.2007; 21: 466–72.
40.
DubertretL., WallachD., SouteyrandP., PerusselM., KalisB., MeynadierJ.Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol.1992; 27: 983–8.
PatelB., SiskinS., KrazmienR., NicholsK., LebwohlM.Compatibility of various topical preparations with calcipotriene ointment. J Invest Dermatol.1997; 108: 658.
43.
RamsayC.A., SchwartzB.E., LowsonD., PappK., BolducA., GilbertM.Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective, and UVB-sparing antipsoriatic combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology.2000; 200(1): 17–24.
44.
WooW.K., McKennaK.E.Combination TL-01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial. Br J Dermatol.2003; 149: 146–50.
45.
FrappazA., TivoletJ.Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol.1993; 3: 351–4.
46.
RingJ., KowalzickL., ChristophersE., SchillW.B., SchöpfE., StänderM.Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol.2001; 144(3): 495–9.
47.
LebwohlM., QuijijeJ., GilliardJ., RollinT., WattsO.Topical calcitriol is degraded by ultraviolet light. J Invest Dermatol.2003; 121(3): 594–5.
48.
HeckerD., MartinezJ., SapadinA., PatelB., LebwohlM.Effect of topical calcipotriene on transmission of ultraviolet light on the stability of calcipotriene. J Invest Dermatol.1995; 104: 659.
49.
LebwohlM., SiskinS.B., EpinetteW., BrenemanD., FunicellaT., KalbR.A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol.1996; 35: 268–9.
50.
LebwohlM., YolesA., LombardiK., LouW.Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: Effects on the duration of improvement. J Am Acad Dermatol.1998; 39: 447–50.
51.
KooJ.Y.New developments in topical sequential therapy for psoriasis. Skin Therapy Lett.2005; 10(9): 1–4.
52.
LahfaM, MrowietzU., KoenigM., SimonJ.C.Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment plaque psoriasis. Eur J Dermatol.2003; 13(3): 261–5.
53.
GuentherL., CambazardF., van de KerhofP.C.M., KragballeK., ChuA.C., TegnerE.Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol.2002; 147: 316–23.
54.
KragballeK., AustadJ., BarnesL., BibbyA., de la BrassinneM., CambazardF.Efficacy results of a 52-week, randomized, double-blind, safety study of a calcopotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology.2006; 213: 319–26.
55.
LugerT., CambazardF., LarsenF.G., BourcierM., GuptaG., ClonierF.A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology.2008; 217: 321–8.
56.
Esgleyes-RibotT., ChandraratnaR.A., LewKayaD.A., SeftonJ., DuvicM.Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol.1994; 103: 88–91.
57.
NonomuraK., YamanishiK., YasunoH., NaraK., HiroseS.Up-regulation of elafin/SKALP gene expression in psoriatic epidermis. Arch Dermatol.1998; 134: 57–60.
58.
WeinsteinG.D., KruegerG.G., LoweN.J., DuvicM., FriedmanD.J., JegasothyB.V.Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol.1997; 37: 85–92.
59.
WeinsteinG.D., KooJ.Y., KruegerG.G., LebwohlM.G., LoweN.J., MenterM.A.Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol.2003; 48: 760–7.
60.
LebwohlM., AstE., CallenJ.P., CullenS.I., HongS.R., Kulp-ShortenC.L.Once-daily tazarotene gel versus twice-daily floucinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol.1998; 38: 705–711.
LebwohlM., BrenemanD., GoffeB.S., GrossmanJ.R., LingM.R., MilbauerJ.Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol.1998; 39: 590–6.
63.
TanghettiE.A.The Tazarotene Stable Plaque Psoriasis Trial Study Group. An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients in patients switched from treatment with calcipotriene +/- corticosteroid. Cutis.2000; 66(6)(Suppl): 12–8.
64.
GollnickH., MenterA.Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol.1999; 140(suppl 54): 18–23.
65.
KaiddbeyK., KopperS.C., SeftonJ., GibsonJ.R.A pilot study to determine the effect of tazarotene 0.1% gel on steroid-induced epidermal atrophy. Int J Dermatol.2001; 40: 468–71.
66.
HeckerD., WorsleyJ., YuehG., LebwohlM.In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol.2000; 42: 1008–11.
67.
LoweN.J.Optimizing therapy: tazarotene in combination with phototherapy. Br J Dermatol.1999; 140(suppl 54): 8–11.
68.
KooJ.Y., LoweN.J., Lew-KayaD.A.Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol.2000; 43: 821–8.
69.
BehrensS., Grundmann-KollamnM., SchienerR., PeterR.U., KerscherM.Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol.2000; 42(3): 493–5.
70.
TzanevaS., HönigsmannH., TanewA., SeeberA.A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. <http://www.ncbi.nlm.nih.gov/pubmed/12366423> Br J Dermatol. 2002 Oct; 147(4): 748–53.
71.
MarslandA.M., GriffithsE.M.The macrolide immunosuppressants in dermatology: mechanism of action. Eur J Dermatol.2002; 12: 618–22.
72.
NghimP., PearsonG., LangleyR.G., Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol.2002; 46: 228–41.
73.
ReitamoS., RissanenJ., RemitzA., GranlundH., ErkkoP., ElgP.Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial. J Invest Dermatol.1998; 111: 396–8.
74.
LebwohlM., FreemanA.K., ChapmanM.S., FeldmanS.R., HartleJ.E., HennningA.Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol.2004; 51: 723–30.
75.
GribetzC., LingM., LebwohlM., Pa riserD., DraelosZ., GottliebA.B.Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind randomized study. J Am Acad Dermatol.2004; 51: 731–8.
76.
NaylorM., ElmetsC., JaraczE., RicoJ.M.Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J Dermatolog Treat.2005; 16(3): 149–53.
77.
ArellanoF.M., WentworthC.E., AranaA., FernándezC., PaulC.F.Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol.2007; 127(4) 808–16.
78.
KooJ.Y., FleischerA.B., AbramovitsW., PariserD.M., McCallC.O., HornT.D.Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: Results in 8000 patients. J Am Acad Dermatol.2005; 53(2)(Suppl 2): S195–205.
79.
HanifinJ.M., PallerA.S., EichenfieldL., ClarkR.A., KormanN., WeinsteinG.U.S. Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol.2005; 53(2)(Suppl 2): S186–94.
80.
PaulC., CorkM., RossiA.B., PappK.A., BarbierN., de ProstY.Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1132 patients treated for up to 2 years. Pediatrics.2006; 117(1): 118–28.
81.
BillichA., AschauerH., AszodiA., StuetzA.Percutaneous absorption of drugs used in atopic eczema: Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm.2004; 269(1): 29–35.
82.
McGillA., FrankA., EmmettN., TurnbullD.M., Birch-MachinM.A., ReynoldsN.J.The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J.2005; 19: 1012–4.
83.
IngramJ.T.Approaches to psoriasis. BMJ.1953; 2: 591–594.
84.
RunneU., KunzeJ.Short-duration (minutes) therapy with dithranol for psoriasis: a new out-patient regimen. Br J Dermatol.1982; 106(2): 135–9.
85.
Van de KerkhofP.C., van der ValkP.G., SwinkelsO.Q., KucharekovaM., de RieM.A., de VriesH.J.A comparison of twice daily calcipotriol ointment with once daily short contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol.2006; 155(4): 800–7.
86.
KraftS., MaibachH.I., ShrootB.Dithranol. In: HowardH.R., editor. Psoriasis, 3rd ed.New York, NY: Marcel Dekker; 1998. pp. 435–52.
87.
LebwohlM.The role of salicylic acid in the treatment of psoriasis. Int J Dermatol.1999; 38: 16–24.
88.
LebwohlM., MartinezJ., WeberP., DeLucaR.Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol.1995; 32(2): 469–71.
89.
FedermanD.G., FroelichC.W., KirsnerR.S.Topical psoriasis therapy. Am Fam Phys.1999; 59(4): 957–64.
90.
KanzlerM.H., GorsulowskyD.C.Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis. Br J Dermatol.1993; 129: 310–4.
91.
GoodfieldM., KownackiS., Berth-JonesJ.Double-blind, randomized, multicenter, parallel group study com paring a 1% coaltar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque sproiasis. J Dermatolog Treat.2004; 15: 14–22.
92.
LeeE., KooJ.Modern Modified “ultra” Goeckerman therapy: A PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and bio logic therapies. J Dermatol Treat.2005; 16(2): 102–107.
93.
MenterA., CramD.L.The Goeckerman regimen in two psoriasis day care centers. J Am Acad Dermatol.1983; (1): 59–65.
94.
Hannuksela-SvahnA., PukkalaE., LaaraE., PoikolainenK., KarvonenJ.Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol.2000; 114: 587–90.
95.
MaughanW.Z., MullerS.A., PerryH.O., PittelkowM.R., O'BrienP.C.Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. A 25–year follow-up study. J Am Acad Dermatol.1980; 3: 612–5.
96.
LamJ., PolifkaJ.E., DohilM.A.Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol.2008; 59: 295–315.
